How can Jubilant Bhartia Group improve its radiopharmaceutical products to increase their shelf life and stability?

Introduction

To improve Jubilant Bhartia Group's radiopharmaceutical products for increased shelf life and stability, we need to conduct a comprehensive analysis of the current product lineup, market demands, and technological advancements in the field. I'll outline a strategic approach to address this challenge, focusing on key stakeholders, pain points, and innovative solutions.

Step 1

Clarifying Questions (5 mins)

• Looking at the radiopharmaceutical industry, I'm thinking about the specific product lines we're focusing on. Could you provide more details on which radiopharmaceutical products we're primarily concerned with improving?

Why it matters: Different radiopharmaceuticals have varying half-lives and stability issues, which will significantly impact our approach. Expected answer: Focus on PET tracers like FDG and PSMA-targeted agents. Impact on approach: Would tailor solutions to short-lived isotopes vs. longer-lived ones.

• Considering the current market landscape, I'm curious about our competitive position. How do our radiopharmaceutical products currently compare to competitors in terms of shelf life and stability?

Why it matters: Helps determine if we're playing catch-up or aiming to leapfrog the competition. Expected answer: We're slightly behind in shelf life for certain products but comparable in stability. Impact on approach: Would focus on rapid improvement in shelf life while maintaining our stability edge.

• Thinking about the end-users, I'm wondering about the primary pain points they experience related to shelf life and stability. What feedback have we received from hospitals and imaging centers using our products?

Why it matters: Ensures we're addressing actual user needs rather than perceived issues. Expected answer: Concerns about product waste due to short shelf life and difficulties in rural distribution. Impact on approach: Would prioritize solutions that extend shelf life and improve logistics for remote areas.

• Considering the regulatory landscape, I'm interested in understanding the current limitations and opportunities. What are the key regulatory constraints or recent changes that might impact our ability to improve shelf life and stability?

Why it matters: Regulatory compliance is crucial in the pharmaceutical industry and will shape our solution space. Expected answer: Recent FDA guidance on extended-release formulations for radiopharmaceuticals. Impact on approach: Would explore novel formulation techniques within the new regulatory framework.